DAWN
Day One Biopharmaceuticals, Inc. NASDAQ Listed May 27, 2021$21.53
Mkt Cap $2.2B
52w Low $5.63
100.0% of range
52w High $21.53
50d MA $18.21
200d MA $10.72
P/E (TTM)
-20.7x
EV/EBITDA
-7.3x
P/B
5.0x
Debt/Equity
0.0x
ROE
-24.3%
P/FCF
-9.3x
RSI (14)
—
ATR (14)
—
Beta
-1.75
50d MA
$18.21
200d MA
$10.72
Avg Volume
4.0M
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
395 Oyster Point Boulevard · Brisbane, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -0.17 | -0.20 | -17.6% | 12.02 | -9.3% | -9.1% | -2.6% | -0.5% | -2.2% | -3.3% | — |
| Nov 4, 2025 | AMC | -0.28 | -0.19 | +31.8% | 7.30 | +8.4% | +25.2% | -1.6% | +8.2% | +4.4% | +2.0% | — |
| Aug 5, 2025 | AMC | -0.35 | -0.29 | +17.1% | 6.88 | -13.5% | -15.7% | +4.0% | +1.2% | -3.3% | +4.1% | — |
| May 6, 2025 | AMC | -0.46 | -0.35 | +23.9% | 6.99 | +7.6% | -9.9% | +7.3% | -4.6% | +2.0% | -3.8% | — |
| Feb 25, 2025 | AMC | -0.35 | -0.69 | -97.1% | 11.82 | -11.9% | -16.5% | -4.4% | -4.0% | -8.9% | +4.2% | — |
| Oct 30, 2024 | AMC | -0.41 | 0.38 | +192.7% | 14.47 | +10.1% | +1.7% | -0.5% | +1.1% | +2.3% | +1.8% | — |
| Jul 30, 2024 | AMC | -0.67 | -0.05 | +92.5% | 15.19 | +0.5% | -5.8% | -1.0% | -1.8% | -4.7% | -1.1% | — |
| May 6, 2024 | AMC | -0.67 | -0.72 | -7.5% | 16.60 | +1.2% | +2.9% | -3.9% | -0.2% | -2.3% | +0.3% | — |
| Feb 26, 2024 | AMC | -0.57 | -0.64 | -12.3% | 15.65 | +0.8% | +11.1% | -3.2% | -0.6% | +4.4% | -3.3% | — |
| Nov 6, 2023 | AMC | -0.60 | -0.54 | +10.0% | 12.19 | +0.7% | +1.4% | -1.8% | -7.6% | +1.2% | +0.4% | — |
| Aug 7, 2023 | AMC | -0.60 | -0.61 | -1.7% | 12.37 | +1.6% | +5.7% | +0.2% | +3.2% | -0.4% | +0.2% | — |
| May 1, 2023 | AMC | -0.60 | -0.59 | +1.7% | 14.47 | +2.1% | -3.4% | +1.6% | -4.4% | +0.7% | -4.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | JP Morgan | Downgrade | Overweight → Neutral | — | $21.28 | $21.27 | -0.0% | -0.1% | +0.1% | +0.2% | +0.2% | -0.3% |
| Mar 10 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $21.33 | $21.28 | -0.2% | -0.2% | -0.1% | +0.1% | +0.2% | +0.2% |
| Mar 9 | Wedbush | Downgrade | Outperform → Neutral | — | $21.20 | $21.19 | -0.0% | +0.6% | -0.2% | -0.1% | +0.1% | +0.2% |
| Mar 6 | Needham | Downgrade | Buy → Hold | — | $12.78 | $21.13 | +65.3% | +65.9% | +0.6% | -0.2% | -0.1% | +0.1% |
| Mar 6 | Jones Trading | Downgrade | Buy → Hold | — | $12.78 | $21.13 | +65.3% | +65.9% | +0.6% | -0.2% | -0.1% | +0.1% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $12.02 | $10.90 | -9.3% | -9.1% | -2.6% | -0.5% | -2.2% | -3.3% |
| Feb 25 | Wedbush | Maintains | Outperform → Outperform | — | $12.02 | $10.90 | -9.3% | -9.1% | -2.6% | -0.5% | -2.2% | -3.3% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.02 | $10.90 | -9.3% | -9.1% | -2.6% | -0.5% | -2.2% | -3.3% |
| Nov 24 | Needham | Maintains | Buy → Buy | — | $8.52 | $8.51 | -0.1% | +4.2% | +6.2% | -0.2% | +0.9% | -7.5% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.52 | $8.51 | -0.1% | +4.2% | +6.2% | -0.2% | +0.9% | -7.5% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $8.99 | $9.07 | +0.9% | +8.2% | +4.4% | +2.0% | -0.2% | -14.4% |
| Nov 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.30 | $7.91 | +8.4% | +25.2% | -1.6% | +8.2% | +4.4% | +2.0% |
| Aug 6 | Needham | Maintains | Buy → Buy | — | $6.88 | $5.95 | -13.5% | -15.7% | +4.0% | +1.2% | -3.3% | +4.1% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.88 | $5.95 | -13.5% | -15.7% | +4.0% | +1.2% | -3.3% | +4.1% |
| May 7 | Needham | Maintains | Buy → Buy | — | $6.99 | $7.52 | +7.6% | -9.9% | +7.3% | -4.6% | +2.0% | -3.8% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.97 | $7.72 | -3.1% | -3.3% | -6.4% | -2.8% | -4.4% | +8.3% |
| Mar 25 | Goldman Sachs | Maintains | Buy → Buy | — | $8.31 | $8.31 | +0.0% | -0.4% | -1.9% | +0.9% | -1.5% | -1.7% |
| Mar 5 | JP Morgan | Maintains | Overweight → Overweight | — | $8.60 | $9.10 | +5.8% | +12.8% | -6.2% | -4.7% | -6.9% | +7.3% |
| Feb 26 | Wedbush | Maintains | Outperform → Outperform | — | $11.82 | $10.41 | -11.9% | -16.5% | -4.4% | -4.0% | -8.9% | +4.2% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.82 | $10.41 | -11.9% | -16.5% | -4.4% | -4.0% | -8.9% | +4.2% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $11.82 | $10.41 | -11.9% | -16.5% | -4.4% | -4.0% | -8.9% | +4.2% |
| Feb 10 | Goldman Sachs | Maintains | Buy → Buy | — | $12.05 | $12.14 | +0.7% | -1.5% | +0.4% | +1.8% | +0.7% | +0.4% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $11.80 | $11.83 | +0.3% | -2.0% | -3.5% | +6.4% | +4.5% | +1.1% |
| Jan 7 | BofA Securities | Maintains | Buy → Buy | — | $12.20 | $12.16 | -0.3% | +1.6% | -1.6% | -3.3% | -2.0% | -3.5% |
| Dec 17 | Jones Trading | Maintains | Buy → Buy | — | $12.62 | $12.44 | -1.4% | +0.2% | -0.9% | -0.6% | +2.6% | -0.8% |
| Oct 31 | Needham | Maintains | Buy → Buy | — | $14.47 | $15.93 | +10.1% | +1.7% | -0.5% | +1.1% | +2.3% | +1.8% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.47 | $15.93 | +10.1% | +1.7% | -0.5% | +1.1% | +2.3% | +1.8% |
| Oct 9 | Needham | Maintains | Buy → Buy | — | $13.69 | $13.69 | +0.0% | +2.6% | -3.7% | +2.6% | +3.0% | +3.7% |
| Aug 6 | JP Morgan | Maintains | Overweight → Overweight | — | $13.26 | $13.42 | +1.2% | -1.1% | -3.0% | +3.2% | +1.3% | +1.4% |
| Aug 1 | BofA Securities | Upgrade | Underperform → Buy | — | $14.31 | $15.13 | +5.7% | -1.0% | -1.8% | -4.7% | -1.1% | -3.0% |
| Aug 1 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $14.31 | $15.13 | +5.7% | -1.0% | -1.8% | -4.7% | -1.1% | -3.0% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.31 | $15.13 | +5.7% | -1.0% | -1.8% | -4.7% | -1.1% | -3.0% |
| Jul 31 | Needham | Maintains | Buy → Buy | — | $15.19 | $15.27 | +0.5% | -5.8% | -1.0% | -1.8% | -4.7% | -1.1% |
| Jul 30 | Needham | Maintains | Buy → Buy | — | $15.36 | $16.27 | +5.9% | -1.1% | -5.8% | -1.0% | -1.8% | -4.7% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.88 | $16.14 | +1.6% | +0.9% | -4.2% | -1.1% | -5.8% | -1.0% |
| Jul 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.71 | $14.82 | +8.1% | +8.0% | +0.5% | -1.1% | +2.7% | +0.7% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.39 | $13.33 | -0.4% | -2.0% | +4.3% | -1.1% | -1.0% | +0.3% |
| Jun 19 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 7 | Needham | Maintains | Buy → Buy | — | $16.60 | $16.80 | +1.2% | +2.9% | -3.9% | -0.2% | -2.3% | +0.3% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.60 | $16.80 | +1.2% | +2.9% | -3.9% | -0.2% | -2.3% | +0.3% |
| Apr 25 | Needham | Maintains | Buy → Buy | — | $15.19 | $14.80 | -2.6% | -13.0% | +12.9% | +10.5% | +3.8% | +3.5% |
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.64 | $16.74 | +0.6% | -8.7% | -13.0% | +12.9% | +10.5% | +3.8% |
| Apr 24 | Needham | Maintains | Buy → Buy | — | $16.64 | $16.74 | +0.6% | -8.7% | -13.0% | +12.9% | +10.5% | +3.8% |
| Apr 22 | JP Morgan | Maintains | Overweight → Overweight | — | $14.96 | $15.39 | +2.9% | +2.8% | +8.2% | -8.7% | -13.0% | +12.9% |
| Mar 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.02 | $15.25 | +1.5% | +3.3% | +1.7% | +4.6% | -2.2% | -2.0% |
| Feb 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.38 | $17.18 | -1.2% | -3.2% | -0.6% | +4.4% | -3.3% | -1.2% |
| Feb 27 | Oppenheimer | Maintains | Perform → Perform | — | $15.65 | $15.77 | +0.8% | +11.1% | -3.2% | -0.6% | +4.4% | -3.3% |
| Feb 27 | Goldman Sachs | Maintains | Buy → Buy | — | $15.65 | $15.77 | +0.8% | +11.1% | -3.2% | -0.6% | +4.4% | -3.3% |
| Nov 7 | Wedbush | Maintains | Outperform → Outperform | — | $12.19 | $12.28 | +0.7% | +1.4% | -1.8% | -7.6% | +1.2% | +0.4% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $12.19 | $12.28 | +0.7% | +1.4% | -1.8% | -7.6% | +1.2% | +0.4% |
No insider trades available.
8-K
Aura Biosciences, Inc. -- 8-K Filing
Aura Biosciences appointed an experienced biopharmaceutical executive as Chief Operating Officer, bringing rare disease development expertise from Hyperion Therapeutics' successful acquisition by Horizon Pharma.
May 4
SC TO-T
!!! Very High
Day One Biopharmaceuticals, Inc. -- Tender Offer
Ajinkyotsu Pharma's tender offer for Day One Biopharmaceuticals (DAWN) will provide shareholders a liquidity event at a predetermined price, though deal terms and valuation details require further disclosure review.
Apr 23
8-K · 5.02
!!! Very High
Day One Biopharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Day One Biopharmaceuticals' tender offer expired with 85.34% of shares validly tendered, indicating substantial shareholder acceptance of the acquisition or recapitalization proposal.
Apr 23
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders have an opportunity to sell shares at a predetermined price in a tender offer, which could provide liquidity but may signal the company faces acquisition or financial challenges requiring external validation.
Apr 14
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders face a potential change of control through this tender offer, making immediate evaluation of the offer price versus intrinsic value critical for deciding whether to accept or reject.
Apr 8
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders can sell shares at a premium price through this tender offer, providing liquidity but potentially signaling an acquisition or significant corporate restructuring ahead.
Mar 26
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders have an opportunity to sell shares at a predetermined price through a tender offer, suggesting potential acquisition or restructuring that could provide liquidity or signal management's view of undervaluation.
Mar 26
8-K
Day One Biopharmaceuticals, Inc. -- 8-K Filing
Day One Biopharmaceuticals (DAWN) has completed an acquisition and filed audited financial statements for the acquired target company, signaling deal closure and integration commencement.
Mar 9
8-K
Day One Biopharmaceuticals, Inc. -- 8-K Filing
Day One Biopharmaceuticals is proceeding with a merger transaction where closing conditions have been substantially satisfied, with no material adverse effects identified affecting the deal's completion.
Mar 6
8-K · 7.01
! Medium
Day One Biopharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Day One Biopharmaceuticals secured a significant revenue opportunity by granting Ipsen exclusive commercialization rights to OJEMDA outside the U.S., expanding the drug's market reach internationally.
Mar 2
8-K · 7.01
! Medium
Day One Biopharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Day One Biopharmaceuticals updated its corporate presentation, likely signaling management's refined messaging to investors about strategy, pipeline progress, or financial outlook.
Feb 24
Data updated apr 25, 2026 4:39am
· Source: massive.com